TW200800957A - New compounds - Google Patents

New compounds

Info

Publication number
TW200800957A
TW200800957A TW095136796A TW95136796A TW200800957A TW 200800957 A TW200800957 A TW 200800957A TW 095136796 A TW095136796 A TW 095136796A TW 95136796 A TW95136796 A TW 95136796A TW 200800957 A TW200800957 A TW 200800957A
Authority
TW
Taiwan
Prior art keywords
dementia
parkinson
solvate
disease
new compounds
Prior art date
Application number
TW095136796A
Other languages
English (en)
Chinese (zh)
Inventor
Stefan Berg
Sven Hellberg
Lars Andersson
Tobias Rein
Dominika Turek
Karin Staaf
Didier Rotticci
Ervan Arzel
Jeremy Burrows
Fernando Huerta
Torben Pedersen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200800957A publication Critical patent/TW200800957A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW095136796A 2005-10-03 2006-10-03 New compounds TW200800957A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0502174 2005-10-03

Publications (1)

Publication Number Publication Date
TW200800957A true TW200800957A (en) 2008-01-01

Family

ID=37906403

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095136796A TW200800957A (en) 2005-10-03 2006-10-03 New compounds

Country Status (20)

Country Link
US (1) US20090105252A1 (es)
EP (1) EP1945628A4 (es)
JP (1) JP2009513575A (es)
KR (1) KR20080059423A (es)
CN (1) CN101326179A (es)
AR (1) AR058073A1 (es)
AU (2) AU2006297890B2 (es)
BR (1) BRPI0616658A2 (es)
CA (1) CA2624875A1 (es)
EC (1) ECSP088405A (es)
IL (1) IL190150A0 (es)
NO (1) NO20082067L (es)
NZ (2) NZ591316A (es)
RU (2) RU2433128C2 (es)
SG (1) SG166125A1 (es)
TW (1) TW200800957A (es)
UA (1) UA92181C2 (es)
UY (1) UY29827A1 (es)
WO (1) WO2007040440A1 (es)
ZA (1) ZA200802897B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
WO2009017455A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
JP5640006B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド ヒストン脱アセチル化酵素および／またはサイクリン依存性キナーゼの縮合複素環式阻害剤
US8134000B2 (en) 2008-07-14 2012-03-13 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
EP2326622A1 (en) 2008-07-28 2011-06-01 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
PE20110843A1 (es) * 2008-09-22 2011-12-08 Cayman Chem Co Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
RU2011140238A (ru) * 2009-04-15 2013-05-20 Астразенека Аб Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
CN102803204A (zh) 2009-06-08 2012-11-28 吉利德科学股份有限公司 环烷基氨基甲酸酯苯酰胺苯胺hdac抑制剂化合物
WO2010144371A1 (en) 2009-06-08 2010-12-16 Gilead Colorado, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
WO2012050517A1 (en) * 2010-10-14 2012-04-19 Astrazeneca Ab Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
JP2017524739A (ja) 2014-07-17 2017-08-31 アンセルムＩｎｓｅｒｍ 神経筋接合部関連疾患の処置方法
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
CN115413278A (zh) * 2020-03-23 2022-11-29 丸仁制药株式会社 新型嘧啶衍生物以及包含其的神经退行性疾病和癌症的预防或治疗用组合物
KR102342803B1 (ko) * 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
CA3197034A1 (en) 2020-10-29 2022-05-05 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
US20240239774A1 (en) * 2021-04-28 2024-07-18 Cornell University Soluble adenylyl cyclase (sac) inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3530710A1 (de) 1985-08-28 1987-03-05 Hoechst Ag Verfahren zur herstellung von halogenphenyl-oxethyl-sulfiden und deren oxidationsprodukten
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
SE0100569D0 (sv) * 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
IL156784A0 (en) * 2001-02-20 2004-02-08 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
KR20040048920A (ko) * 2001-11-01 2004-06-10 얀센 파마슈티카 엔.브이. 글리코겐 신타아제 키나제 3-베타 저해제(ｇｓｋ저해제)로서의 헤테로아릴 아민
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) * 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
WO2004005283A1 (en) * 2002-07-09 2004-01-15 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
EP1611125A1 (en) * 2003-02-07 2006-01-04 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
DE602004024374D1 (de) * 2003-03-13 2010-01-14 Vertex Pharma Zusammensetzungen zur verwendung als protein-kinase-inhibitoren
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
BRPI0412351A (pt) * 2003-07-30 2006-09-05 Cyclacel Ltd derivados e piridilamino-pirimidina como inibidores de proteìna quinase
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US7132651B2 (en) 2004-04-23 2006-11-07 Framatome Anp, Inc. In-situ BWR and PWR CRUD flake analysis method and tool
AU2006274733B2 (en) * 2005-07-30 2010-09-16 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
RU2011140238A (ru) * 2009-04-15 2013-05-20 Астразенека Аб Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера

Also Published As

Publication number Publication date
SG166125A1 (en) 2010-11-29
AU2006297890A1 (en) 2007-04-12
RU2433128C2 (ru) 2011-11-10
AR058073A1 (es) 2008-01-23
UY29827A1 (es) 2007-05-31
EP1945628A4 (en) 2010-06-02
AU2011200948A1 (en) 2011-03-24
NO20082067L (no) 2008-07-02
EP1945628A1 (en) 2008-07-23
BRPI0616658A2 (pt) 2011-06-28
CA2624875A1 (en) 2007-04-12
ECSP088405A (es) 2008-05-30
NZ591316A (en) 2012-06-29
IL190150A0 (en) 2008-08-07
KR20080059423A (ko) 2008-06-27
UA92181C2 (ru) 2010-10-11
US20090105252A1 (en) 2009-04-23
RU2011115406A (ru) 2012-10-27
NZ566804A (en) 2011-03-31
ZA200802897B (en) 2008-12-31
RU2008110910A (ru) 2009-11-10
CN101326179A (zh) 2008-12-17
WO2007040440A1 (en) 2007-04-12
AU2006297890B2 (en) 2011-04-28
JP2009513575A (ja) 2009-04-02

Similar Documents

Publication Publication Date Title
TW200800957A (en) New compounds
TW200745111A (en) New compounds
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
TW200606164A (en) New compounds
SE0104340D0 (sv) New compounds
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
NO20090328L (no) Nye forbindelser 385
DE60318193D1 (en) Phenethanolaminderivate
WO2008002244A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
TW200619220A (en) New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
WO2007022380A3 (en) Bis-aryl amide compounds and methods of use
TW200800984A (en) New compounds
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
SG137850A1 (en) Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
UY27593A1 (es) Nuevos compuestos
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases